Ion AmpliSeq Technology Changed Targeted Next-Generation Sequencing, Precision Oncology Research Followed

When most labs were struggling to multiplex a small handful of PCR targets, Thermo Fisher Scientific invented and developed Ion AmpliSeq technology, a multiplex PCR enrichment strategy that enabled thousands of targets to be amplified simultaneously, in a single day, even from FFPE material. This made targeted next-generation sequencing practical for laboratories handling limited, degraded, and otherwise challenging clinical research samples at scale.

Another important milestone in the evolution of the Ion AmpliSeq portfolio was the introduction of the Ion AmpliSeq Designer tool, which allowed researchers to design custom targeted NGS testing panels for many clinical research applications using the same underlying multiplex PCR architecture as commercial assays. At a time when custom panel development often required substantial assay engineering expertise, Ion AmpliSeq Designer helped democratize targeted sequencing by enabling laboratories to rapidly create application-specific research panels for oncology research, inherited disease, immunology, microbial surveillance, and translational research.

The availability of a cloud-based panel design environment also reinforced one of the defining characteristics of the broader Ion AmpliSeq ecosystem: tight integration between assay design, sequencing chemistry optimization, sequencing workflows and instrumentation, and downstream analysis and reporting. This combination helped accelerate adoption among translational research laboratories seeking more flexible alternatives to fixed-content sequencing panels.

That shift helped alter the trajectory of targeted sequencing.

The impact of Ion AmpliSeq was closely tied to timing. Precision oncology research was moving away from single-gene testing toward multiplex biomarker profiling, but research sample tissue availability was becoming an increasingly important limitation. Clinical lung cancer research workflows illustrated the challenge particularly well. Small amounts of samples often need to support histology, immunohistochemistry, PD-L1 testing, and molecular profiling simultaneously for clinical research, frequently from only a few FFPE sections.

Ion AmpliSeq-based sequencing aligned naturally with these constraints and tolerates DNA and RNA fragmentation better than other enrichment approaches. The ability to work with only 10 ng of DNA or RNA per reaction fundamentally changed what laboratories considered “sequenceable” material.

Several recent studies illustrate how the operational advantages mediated by Ion AmpliSeq technology translated into practice. Investigators using the Oncomine Comprehensive Assay, Oncomine Comprehensive Assay Plus, Oncomine Precision Assay GX and Oncomine Focus Assay reported successful sequencing from bronchoscopic samples, pleural fluid pellets, cytology-derived material, and low-input FFPE samples across NSCLC, breast cancer, and liquid biopsy applications in a clinical research setting.¹

Turnaround time, from biological sample to report, became equally important. As clinical research on the development of targeted therapies expanded, the sequencing workflow itself increasingly influenced timely decision-making. Other NGS methods, like hybridization-based enrichment, often require overnight incubation and multiple post-capture processing steps. Ion AmpliSeq workflows simplified much of that process. In the peer-reviewed UTOPIA clinical research pilot study, investigators reported comprehensive genomic reporting within 72 hours using integrated Genexus workflows for NSCLC biomarker testing.² 

Importantly, these differences extend beyond laboratory convenience. Faster workflows can support faster molecular testing, improve operational efficiency, and enable more laboratories to perform targeted sequencing locally rather than relying on sending the clinical research samples to centralized reference laboratories.

The durability of Ion AmpliSeq was not driven by PCR chemistry alone. Thermo Fisher Scientific built an integrated sequencing environment around the technology that combined assay design, semiconductor sequencing, automated analysis and eventually end-to-end workflow automation – including automating the NGS library preparation step in the workflow.

That integration became increasingly important as molecular testing in clinical research expanded beyond specialized genomics centers into regional hospitals and translational research laboratories. Automated workflows reduced hands-on time, decreased variability, and lowered some of the infrastructure barriers historically associated with NGS implementation.

The broader sequencing industry also recognized the value of Ion AmpliSeq technology. Another large NGS solutions manufacturer licensed aspects of Ion AmpliSeq technology, reflecting the influence and power of this innovation. 
Thermo Fisher Scientific, however, remains the primary architect of the chemistry, assay optimization strategies, integrated workflows, and automation infrastructure that continue to shape modern Ion AmpliSeq-based sequencing.

Because Thermo Fisher Scientific developed both the underlying chemistry and the surrounding NGS workflow ecosystem, Ion AmpliSeq evolved as more than a library preparation method. It became a tightly integrated sequencing architecture spanning assay design, NGS instrumentation, automation, and translational workflow implementation.

At the same time, Ion AmpliSeq workflows retained a distinct identity within the market. Ion AmpliSeq never intended to replace whole genome sequencing. Instead, it was developed to occupy a different operational niche: rapid, easy, automated, high-efficiency sequencing optimized for targeted biomarker detection from challenging specimens.

Comparisons between amplicon-based sequencing with Ion AmpliSeq technology and hybrid-capture sequencing are often framed as technological competition, but in practice the two approaches were developed to address different laboratory priorities.

Ion AmpliSeq workflows emphasize speed, easy to automate, low-input compatibility, and deep targeted coverage. Hybrid-capture workflows prioritize broader genomic interrogation, structural variant characterization, and discovery-oriented profiling. Those distinctions remain visible in workflow architecture today.

Comparison table: Amplicon versus hybrid-capture workflows

Values reflect generalized characteristics derived from published oncology sequencing studies and operational laboratory experience. Actual performance depends on assay design, specimen quality, sequencing configuration, and bioinformatics pipelines.

Technologies are often remembered for the scientific problems they solve. Ion AmpliSeq technology helped address an important one.

By enabling highly multiplexed targeted sequencing from limited, degraded, and challenging specimens, it contributed to making targeted NGS practical for a much broader range of molecular laboratories. Workflow simplicity, low nucleic acid input requirements, and compatibility with difficult specimens supported the expansion of targeted sequencing beyond specialized genomics centers into routine translational molecular profiling.

More than a decade later, sequencing technologies continue to evolve, but many of the laboratory challenges that originally drove the development of multiplex PCR remain familiar. Limited specimen material, fragmented FFPE-derived nucleic acid, and the need for efficient workflows continue to influence sequencing strategy selection.

Rather than competing or trying to replace one another, amplicon- and hybrid-capture-based sequencing have matured into complementary technologies. Laboratories increasingly select each approach according to specimen characteristics, workflow priorities, and research objectives, allowing targeted sequencing strategies to be matched to the biological questions being investigated.

What is Ion AmpliSeq technology?

Ion AmpliSeq is a multiplex PCR-based targeted sequencing technology developed within the Thermo Fisher Scientific for rapid NGS library preparation from low amounts of DNA and RNA.

Why did Ion AmpliSeq become widely adopted in clinical oncology research?

The technology aligned well with the operational realities of clinical oncology research laboratories, particularly limited tissue availability, degraded FFPE-derived nucleic acids, and the need for rapid biomarker reporting.

How is Ion AmpliSeq amplicon sequencing different from hybrid capture?

Ion AmpliSeq amplicon-based sequencing enriches predefined genomic regions using multiplex PCR amplification, while hybrid-capture workflows enrich targets through probe hybridization. Ion AmpliSeq workflows are generally faster and lower input, whereas hybrid capture typically supports broader genomic characterization.

Why are low-input workflows important in translational research sequencing?

Many clinical research and translational research specimens yield very limited nucleic acid quantities. Low-input workflows help preserve tissue and expand access to multiplex molecular profiling for small or degraded samples.

Is Ion AmpliSeq amplicon going to completely replace hybrid capture sequencing?

No, hybrid capture is still used for applications where sample quality is high and turnaround time is less important.